Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAZZLE: Delamanid-containing Regimen for MDR-TB
NCT02975570Phase 3Withdrawn
- Sponsor
- Boston University
- Start
- Aug 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of delamanid in Tuberculosis (TB) (6 arms), sponsored by Boston University. Primary endpoint: Successful outcome at 18 months. Planned start Aug 2017; status: withdrawn.
02
Drugs
delamanid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02975570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975570.